These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 17333554)

  • 1. First treatment for Hunter syndrome.
    FDA Consum; 2006; 40(6):5. PubMed ID: 17333554
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment for Hunter syndrome approved.
    FDA Consum; 2006; 40(5):4. PubMed ID: 17328099
    [No Abstract]   [Full Text] [Related]  

  • 3. Idursulfase: a poor risk-benefit balance in type II mucopolysaccharidosis.
    Prescrire Int; 2008 Jun; 17(95):109. PubMed ID: 18630351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hunter syndrome: resolution of extensive typical skin lesions after 9 months of enzyme replacement therapy with idursulfase.
    Marín LL; Gutiérrez-Solana LG; Fernández AT
    Pediatr Dermatol; 2012; 29(3):369-70. PubMed ID: 21995841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hunter disease before and during enzyme replacement therapy.
    Hoffmann B; Schulze-Frenking G; Al-Sawaf S; Beck M; Mayatepek E
    Pediatr Neurol; 2011 Sep; 45(3):181-4. PubMed ID: 21824567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early response to idursulfase treatment in a 3 year-old boy affected of Hunter syndrome.
    Galán-Gómez E; Guerrero-Rico A; Cáceres-Marzal C; Zambrano-Castaño M; Moreno-Tejero ML; Grande-Tejada AM; Fernández-Hernández S; Vaquerizo-Madrid J; Cardesa-García JJ
    Eur J Med Genet; 2008; 51(3):268-71. PubMed ID: 18396123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First experience of enzyme replacement therapy with idursulfase in Spanish patients with Hunter syndrome under 5 years of age: case observations from the Hunter Outcome Survey (HOS).
    Alcalde-Martín C; Muro-Tudelilla JM; Cancho-Candela R; Gutiérrez-Solana LG; Pintos-Morell G; Martí-Herrero M; Munguira-Aguado P; Galán-Gómez E
    Eur J Med Genet; 2010; 53(6):371-7. PubMed ID: 20709629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome).
    Muenzer J; Gucsavas-Calikoglu M; McCandless SE; Schuetz TJ; Kimura A
    Mol Genet Metab; 2007 Mar; 90(3):329-37. PubMed ID: 17185020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rare diseases, orphan drugs, and orphaned patients.
    Scheindlin S
    Mol Interv; 2006 Aug; 6(4):186-91. PubMed ID: 16960139
    [No Abstract]   [Full Text] [Related]  

  • 10. Multidisciplinary management of Hunter syndrome.
    Muenzer J; Beck M; Eng CM; Escolar ML; Giugliani R; Guffon NH; Harmatz P; Kamin W; Kampmann C; Koseoglu ST; Link B; Martin RA; Molter DW; Muñoz Rojas MV; Ogilvie JW; Parini R; Ramaswami U; Scarpa M; Schwartz IV; Wood RE; Wraith E
    Pediatrics; 2009 Dec; 124(6):e1228-39. PubMed ID: 19901005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health care policy. Reforming off-label promotion to enhance orphan disease treatment.
    Liang BA; Mackey T
    Science; 2010 Jan; 327(5963):273-4. PubMed ID: 20075234
    [No Abstract]   [Full Text] [Related]  

  • 12. [Clinical study of enzyme replacement therapy with idursulfase].
    Gutiérrez-Solana LG
    Rev Neurol; 2007 Feb; 44 Suppl 1():S7-S11. PubMed ID: 17345556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adopting orphan drugs--two dozen years of treating rare diseases.
    Haffner ME
    N Engl J Med; 2006 Feb; 354(5):445-7. PubMed ID: 16452556
    [No Abstract]   [Full Text] [Related]  

  • 14. The routes to orphan drug designation--our recent experience at the FDA.
    Lev D; Thorat C; Phillips I; Thomas M; Imoisili MA
    Drug Discov Today; 2012 Feb; 17(3-4):97-9. PubMed ID: 22210120
    [No Abstract]   [Full Text] [Related]  

  • 15. Glycosaminoglycans can be associated with oxidative damage in mucopolysaccharidosis II patients submitted to enzyme replacement therapy.
    Negretto GW; Deon M; Biancini GB; Burin MG; Giugliani R; Vargas CR
    Cell Biol Toxicol; 2014 Aug; 30(4):189-93. PubMed ID: 25022704
    [No Abstract]   [Full Text] [Related]  

  • 16. Idursulfase for the treatment of mucopolysaccharidosis II.
    Clarke LA
    Expert Opin Pharmacother; 2008 Feb; 9(2):311-7. PubMed ID: 18201153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Should off-label drug use be off-the-table?
    Rivkees SA
    J Pediatr Endocrinol Metab; 2007 Feb; 20(2):171-2. PubMed ID: 17396432
    [No Abstract]   [Full Text] [Related]  

  • 18. What the Orphan Drug Act has done lately for children with rare diseases: a 10-year analysis.
    Thorat C; Xu K; Freeman SN; Bonnel RA; Joseph F; Phillips MI; Imoisili MA
    Pediatrics; 2012 Mar; 129(3):516-21. PubMed ID: 22371464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IgE-mediated anaphylaxis and allergic reactions to idursulfase in patients with Hunter syndrome.
    Kim J; Park MR; Kim DS; Lee JO; Maeng SH; Cho SY; Han Y; Ahn K; Jin DK
    Allergy; 2013 Jun; 68(6):796-802. PubMed ID: 23621439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Show drugs work before selling them.
    Sipp D; McCabe C; Rasko JE
    Nature; 2017 Mar; 543(7644):174-175. PubMed ID: 28277530
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.